China Biotech Services Holdings Limited (8037) completed the issuance of convertible bonds under a specific mandate in the aggregate principal amount of US$35.00 million on February 20, 2026. Upon full conversion of these bonds at the agreed conversion price, the total number of shares would increase from 975.73 million to approximately 1.39 billion, with the subscriber’s stake at 29.72%.

Prior to this issuance, there were outstanding 2024 convertible bonds amounting to US$6.00 million. Following completion of the new issuance on February 20, 2026, the conversion price of these 2024 convertible bonds was adjusted from HK$1.20 to HK$1.11 per share. As a result, the maximum number of shares issuable under full conversion of the 2024 convertible bonds rose to around 42.43 million shares. All other terms of the 2024 convertible bonds remain unchanged.